Aprea Therapeutics, Inc.

Pharmaceutical company · Doylestown, Pennsylvania, United States · Nasdaq: APRE

Aprea Therapeutics, Inc. is a pharmaceutical company headquartered in Doylestown, Pennsylvania, United States. Its shares trade on Nasdaq under the ticker APRE. It has received 1 US government small-business research award (SBIR/STTR) from health agencies, $2 million in total, most recently in 2023. It has reported private securities offerings to the US SEC, most recently $3.1 million sold in a notice filed in 2025.

www.aprea.comProfile compiled from public records. Is this your company? Request a correction or update

Aprea Therapeutics at a glance

Typepharmaceutical company
HeadquartersDoylestown, Pennsylvania, United States
Stock listingNasdaq: APRE
SEC industryPharmaceutical Preparations
Employees (per SBIR records)10
SEC CIK1781983

What does Aprea Therapeutics do?

US government research funding

1 SBIR/STTR small-business research award from US health agencies, $2 million in total (2023). NIH funding came from the National Cancer Institute.

Private fundraising reported to the SEC

1 Form D notice; the most recent reported $3.1 million sold (2025).

Frequently asked questions about Aprea Therapeutics

Where is Aprea Therapeutics headquartered?

Aprea Therapeutics, Inc. is headquartered in Doylestown, Pennsylvania, United States.

What does Aprea Therapeutics do?

Aprea Therapeutics, Inc. is a pharmaceutical company. Its SEC industry classification is Pharmaceutical Preparations.

Is Aprea Therapeutics a public company?

Yes. Aprea Therapeutics, Inc. trades on Nasdaq under the ticker APRE.

Similar companies

Need a CRO or CDMO for your next study?

Compare transparent quotes from research and manufacturing partners, then contract once. Free for buyers.

Compare quotes

Sources

Location data: GeoNames (geonames.org), CC BY 4.0.

Last updated 2026-09-23.